Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Galmed Pharmaceuticals Price Performance NASDAQ:GLMD opened at $0.36 on Tuesday. The company’s 50 day moving average price is $0.40 and its 200-day moving average […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom , ,News Ratings For Galmed Pharmaceuticals Daily ,Galmed Pharmaceuticals Ltd ,Millennium Management ,Raymond James Financial Services Advisors Inc ,Walleye Capital ,Institutional Trading Of Galmed Pharmaceuticals ,Nasdaq ,Galmed Pharmaceuticals ,Cambridge Investment Research Advisors Inc ,Galmed Pharmaceuticals Price Performance ,Galmed Pharmaceuticals Company Profile ,Free Report ,Get Free Report ,James Financial Services Advisors ,Cambridge Investment Research Advisors ,Pharmaceuticals Ltd ,Galmed Pharmaceuticals Daily ,Nasdaq Glmd ,Glmd ,Medical ,Initiated Coverage ,Stocknews Com ,